These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 28748450)

  • 21. Systematic Review of Model-Based Economic Evaluations of Treatments for Alzheimer's Disease.
    Hernandez L; Ozen A; DosSantos R; Getsios D
    Pharmacoeconomics; 2016 Jul; 34(7):681-707. PubMed ID: 26899832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Value for money in the health sector: the contribution of primary health care.
    Mills A; Drummond M
    Health Policy Plan; 1987 Jun; 2(2):107-28. PubMed ID: 10312103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic narrative review of decision frameworks to select the appropriate modelling approaches for health economic evaluations.
    Tsoi B; O'Reilly D; Jegathisawaran J; Tarride JE; Blackhouse G; Goeree R
    BMC Res Notes; 2015 Jun; 8():244. PubMed ID: 26081877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The affordability of antiretroviral therapy in developing countries: what policymakers need to know.
    Forsythe SS
    AIDS; 1998; 12 Suppl 2():S11-8. PubMed ID: 9792357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Presentation of economic evaluation results.
    Chaikledkaew U; Teerawattananon Y
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S66-73. PubMed ID: 19253489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What Guidance are Economists Given on How to Present Economic Evaluations for Policymakers? A Systematic Review.
    Sullivan SM; Wells G; Coyle D
    Value Health; 2015 Sep; 18(6):915-24. PubMed ID: 26409620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic Evaluations of Multicomponent Disease Management Programs with Markov Models: A Systematic Review.
    Kirsch F
    Value Health; 2016 Dec; 19(8):1039-1054. PubMed ID: 27987631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Aspects of economic evaluation in health care].
    Noelle G; Jaskulla E; Sawicki PT
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Jan; 49(1):28-33. PubMed ID: 16341607
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users.
    Vemer P; Corro Ramos I; van Voorn GA; Al MJ; Feenstra TL
    Pharmacoeconomics; 2016 Apr; 34(4):349-61. PubMed ID: 26660529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application.
    Sculpher M; Fenwick E; Claxton K
    Pharmacoeconomics; 2000 May; 17(5):461-77. PubMed ID: 10977388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis.
    Alemao E; Al MJ; Boonen AA; Stevenson MD; Verstappen SMM; Michaud K; Weinblatt ME; Rutten-van Mölken MPMH
    PLoS One; 2018; 13(10):e0205013. PubMed ID: 30289926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond.
    Rocchi A; Menon D; Verma S; Miller E
    Value Health; 2008; 11(4):771-83. PubMed ID: 18179658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A systematic review of lower extremity arterial revascularization economic analyses.
    Moriarty JP; Murad MH; Shah ND; Prasad C; Montori VM; Erwin PJ; Forbes TL; Meissner MH; Stoner MC;
    J Vasc Surg; 2011 Oct; 54(4):1131-1144.e1. PubMed ID: 21971093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Balancing costs and benefits at different stages of medical innovation: a systematic review of Multi-criteria decision analysis (MCDA).
    Wahlster P; Goetghebeur M; Kriza C; Niederländer C; Kolominsky-Rabas P;
    BMC Health Serv Res; 2015 Jul; 15():262. PubMed ID: 26152122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reviewing the evidence to inform the population of cost-effectiveness models within health technology assessments.
    Kaltenthaler E; Tappenden P; Paisley S
    Value Health; 2013; 16(5):830-6. PubMed ID: 23947977
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dedicated Perioperative Hip Fracture Comanagement Programs are Cost-effective in High-volume Centers: An Economic Analysis.
    Swart E; Vasudeva E; Makhni EC; Macaulay W; Bozic KJ
    Clin Orthop Relat Res; 2016 Jan; 474(1):222-33. PubMed ID: 26260393
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis.
    Green C
    Pharmacoeconomics; 2007; 25(9):735-50. PubMed ID: 17803333
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using whole disease modeling to inform resource allocation decisions: economic evaluation of a clinical guideline for colorectal cancer using a single model.
    Tappenden P; Chilcott J; Brennan A; Squires H; Glynne-Jones R; Tappenden J
    Value Health; 2013 Jun; 16(4):542-53. PubMed ID: 23796288
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.